Dudediligence.

Altimmune, Inc

ALTNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$5,000Sep ’24$5,000Dec ’24$5,000Mar ’25$5,000Jun ’25$5,000Sep ’25$26,000Dec ’25
Net income, by quarter
−$22.8MSep ’24−$23.2MDec ’24−$19.6MMar ’25−$22.1MJun ’25−$19.0MSep ’25−$27.4MDec ’25−$22.6MMar ’26−$22.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$4.4M−$68,000$426,000$20,000$41,000
Operating income−$96.9M−$87.7M−$95.9M−$103.2M−$94.5M
Net income−$97.1M−$84.7M−$88.4M−$95.1M−$88.1M
Operating cash flow−$78.2M−$62.6M−$75.8M−$79.8M−$67.5M
Free cash flow−$90.4M−$62.7M−$75.9Mnone on file−$67.5M
Cash$190.3M$111.1M$135.1M$36.9M$43.8M
Debt$1.5Mnone on filenone on filenone on file$34.3M
Shares outstanding41.0M49.2M70.7M72.4M110.9M